1339 related items for PubMed ID: 11393383
1. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
Petersen LJ, Petersen JR, Talleruphuus U, Møller ML, Ladefoged SD, Mehlsen J, Jensen HA.
Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
[Abstract] [Full Text] [Related]
2. The effects of isradipine and spirapril as monotherapy and combined therapy on blood pressure, renal hemodynamics, natriuresis, and urinary kallikrein in hypertensive nephropathy.
Maccariello ER, Genelhu de Abreu Fagundes V, Francischetti EA.
Am J Hypertens; 1997 May; 10(5 Pt 1):541-5. PubMed ID: 9160765
[Abstract] [Full Text] [Related]
3. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z, Amlodipine Versus Enalapril in Renal failure (AVER) Study Group.
Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
[Abstract] [Full Text] [Related]
4. Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension.
Shohat J, Wittenberg C, Erman A, Rosenfeld J, Boner G.
Scand J Urol Nephrol; 1999 Feb; 33(1):57-62. PubMed ID: 10100366
[Abstract] [Full Text] [Related]
5. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T.
Arch Intern Med; 2005 Apr 25; 165(8):936-46. PubMed ID: 15851647
[Abstract] [Full Text] [Related]
6. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM.
Am J Kidney Dis; 2009 Apr 25; 53(4):606-16. PubMed ID: 19216016
[Abstract] [Full Text] [Related]
7. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).
Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R, Gaspari F, Remuzzi G.
Kidney Int Suppl; 1997 Dec 25; 63():S54-7. PubMed ID: 9407422
[Abstract] [Full Text] [Related]
8. [Kidney function in hypertensive patients with chronic renal failure treated with the dual eliminated ACE-inhibitor spirapril].
Haufe CC, Sierakowski B, Jansa U, Stein G.
Med Klin (Munich); 1994 Aug 15; 89(8):416-20. PubMed ID: 7968874
[Abstract] [Full Text] [Related]
9. Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension.
Pittrow DB, Antlsperger A, Welzel D, Wambach G, Schardt W, Weidinger G.
Cardiovasc Drugs Ther; 1997 Nov 15; 11(5):619-27. PubMed ID: 9493699
[Abstract] [Full Text] [Related]
10. Strict blood-pressure control and progression of renal failure in children.
ESCAPE Trial Group, Wühl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Möller K, Wigger M, Peruzzi L, Mehls O, Schaefer F.
N Engl J Med; 2009 Oct 22; 361(17):1639-50. PubMed ID: 19846849
[Abstract] [Full Text] [Related]
11. Spirapril in chronic renal failure.
Stein G, Sierakowski B, Jansa U, Haufe CC.
Blood Press Suppl; 1994 Oct 22; 2():54-60. PubMed ID: 8061847
[Abstract] [Full Text] [Related]
12. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, O'Brien RC, Raffaele J, Tsalamandris C, Melbourne Diabetic Nephropathy Study Group.
Diabet Med; 2004 Nov 22; 21(11):1192-9. PubMed ID: 15498085
[Abstract] [Full Text] [Related]
13. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?
van Essen GG, Apperloo AJ, Rensma PL, Stegeman CA, Sluiter WJ, de Zeeuw D, de Jong PE.
Kidney Int Suppl; 1997 Dec 22; 63():S58-62. PubMed ID: 9407423
[Abstract] [Full Text] [Related]
14. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
Miranda RD, Mion D, Rocha JC, Kohlmann O, Gomes MA, Saraiva JF, Amodeo C, Filho BL.
Clin Ther; 2008 Sep 22; 30(9):1618-28. PubMed ID: 18840367
[Abstract] [Full Text] [Related]
15. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M.
Am J Hypertens; 2004 Jun 22; 17(6):495-501. PubMed ID: 15177521
[Abstract] [Full Text] [Related]
16. Effect of lacidipine, a dihydropyridine calcium antagonist on renal function of hypertensive patients with renal insufficiency.
Bailey RR, Shand BI, Smith AH, Robson RA, Lynn KL.
Clin Nephrol; 1997 Oct 22; 48(4):224-9. PubMed ID: 9352156
[Abstract] [Full Text] [Related]
17. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G.
N Engl J Med; 1994 Mar 31; 330(13):877-84. PubMed ID: 8114857
[Abstract] [Full Text] [Related]
18. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.
Katayama S, Kawamori R, Iwamoto Y, Saito I, Kuramoto K, ATTEST Study Group.
Hypertens Res; 2008 Aug 31; 31(8):1499-508. PubMed ID: 18971523
[Abstract] [Full Text] [Related]
19. Effect of light exercise on renal hemodynamics in patients with hypertension and chronic renal disease.
Svarstad E, Myking O, Ofstad J, Iversen BM.
Scand J Urol Nephrol; 2002 Aug 31; 36(6):464-72. PubMed ID: 12623513
[Abstract] [Full Text] [Related]
20. Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study.
O'Donnell MJ, Rowe BR, Lawson N, Horton A, Gyde OH, Barnett AH.
J Hum Hypertens; 1993 Aug 31; 7(4):333-9. PubMed ID: 8410924
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
